Supriya Lifescience Peer Comparison

NSE: SUPRIYA | BSE: 543434

₹847.30

₹-22.00 (-2.53%)

As on 30-Oct-2026IST

Market cap

₹6,810 Cr

Revenue (TTM)

₹873 Cr

P/E Ratio

34.3

P/B Ratio

5.6

Div. Yield

0.1 %

Edit

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	6,810	18,671	17,672	16,867	16,088
Revenue (₹ Cr)	873	1,682	2,287	2,570	3,330
Net Profit (₹ Cr)	198.37	273.51	678.07	735.15	720.77
Net Margin (%)	22.44	16.19	28.10	26.88	21.60
RoE (%)	17.43	11.15	19.73	19.16	18.93
Price to Earnings	34.33	62.80	26.56	22.94	22.74
Price-To-Book	5.57	6.95	4.81	3.83	3.88

Income Statement (₹ Cr)

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	872.55	1,682.47	2,287.33	2,569.77	3,329.63
Total Income	884.01	1,689.83	2,413.29	2,735.39	3,337.47
Total Expenditure	582.74	1,203.91	1,490.75	1,628.14	2,168.88
EBITDA	289.80	478.55	796.58	941.63	1,160.75
Depreciation	30.90	126.01	78.10	57.58	285.40
EBIT	258.91	352.55	718.48	884.05	875.35
Interest	1.75	52.11	0.88	7.69	187.51
Other Income	11.46	7.37	125.96	165.62	7.84
Exceptional Items	-0.46	12.16	0.00	-49.16	-53.14
Profit before Tax	268.16	319.96	843.56	992.82	642.54
Provision for Tax	69.79	46.45	165.49	257.67	-78.23
Profit after Tax	198.37	273.51	678.07	735.15	720.77

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	1,197.73	2,591.20	3,586.42	4,202.90	4,144.34
Minority Interest	0.00	0.00	-12.71	0.00	-10.85
Non-Current Liabilities	38.33	266.35	28.74	91.50	758.48
Current Liabilities	121.04	848.06	385.94	627.48	2,681.14
Total Liabilities	1,357.11	3,705.61	4,037.51	4,921.88	7,246.72

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	818.70	2,525.44	1,291.22	770.28	5,578.78
Current Assets	532.30	1,109.77	2,585.66	3,803.22	1,800.86
Total Assets	1,357.11	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	0.00	657.97	0.57	2.50	2,309.68
Net Current Assets	411.26	261.71	2,199.72	3,175.74	-880.28
Contingent Liabilities	8.81	160.01	17.53	370.49	51.57

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	185.77	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-176.17	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	-9.88	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	-0.29	29.88	-105.52	-392.41	-145.00

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	25.30	11.43	24.97	23.39	14.47
ROE (%)	17.43	11.15	19.73	19.16	18.93
ROA (%)	16.07	7.80	18.69	14.95	9.78
EBIT Margin (%)	29.67	20.95	31.41	34.40	26.29
Net Margin (%)	22.44	16.19	28.10	26.88	21.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	28.14	27.91	15.01	10.69	11.06
EBIT Growth (%)	13.70	58.32	18.45	24.14	13.71
Net Profit Growth (%)	11.38	149.56	19.61	-9.09	60.98
EPS Growth (%)	11.57	-3.57	17.73	14.40	80.38
Book Value Growth (%)	20.16	9.67	26.75	-0.34	36.71

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	34.27	66.62	26.56	21.86	21.06
Price / Book Value	5.57	6.95	4.81	3.83	3.88
Dividend Yield (%)	0.12	0.06	0.34	2.03	0.00
EV/EBITDA	23.23	40.30	20.92	14.61	15.79
Market Cap (₹ Cr)	4,548.18	6,819.66	11,439.22	21,592.90	17,980.08

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.07	0.00	0.00	0.10
Short term debt to equity ratio	--	0.16	0.00	0.00	0.12
Current Ratio	4.40	1.31	6.70	6.06	0.67
Quick Ratio	3.08	0.88	5.59	5.31	0.49
Interest Coverage	154.15	7.14	959.59	130.11	4.43

	Supriya Lifescience	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	25.15	30.84	36.10	7.07	18.98
Asset Turnover	0.71	0.48	0.63	0.52	0.45
Receivable days	70.59	113.81	121.68	26.06	63.88
Inventory Days	55.45	84.76	63.83	65.95	43.27
Payable days	133.19	101.94	108.28	81.01	151.85
Cash Conversion Cycle	-7.15	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.